The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis

Atopic dermatitis (AD), a common chronic inflammatory skin disease, is characterized by inflammatory cell skin infiltration. The JAK-STAT pathway has been shown to play an essential role in the dysregulation of immune responses in AD, including the exaggeration of Th2 cell response, the activation of eosinophils, the maturation of B cells, and the suppression of regulatory T cells (Tregs). In addition, the JAK-STAT pathway, activated by IL-4, also plays a critical role in the pathogenesis of AD by upregulating epidermal chemokines, pro-inflammatroy cytokines, and pro-angiogenic factors as well as by downregulating antimicrobial peptides (AMPs) and factors responsible for skin barrier function. In this review, we will highlight the recent advances in our understanding of the JAK-STAT pathway in the pathogenesis of AD.

• Publication year

  2013

• Venue

  JAK-STAT

• Publication date

  2013-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4161/jkst.24137PMID 24069552PMCID 3772104
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Th2 cytokine, interleukin‐4, abrogates the cohesion of normal stratum corneum in mice: implications for pathogenesis of atopic dermatitis

  2013cited by this paper
• IL-4 up-regulates epidermal chemotactic, angiogenic, and pro-inflammatory genes and down-regulates antimicrobial genes in vivo and in vitro: relevant in the pathogenesis of atopic dermatitis.

  2013cited by this paper
• IL-9 Induces VEGF Secretion from Human Mast Cells and IL-9/IL-9 Receptor Genes Are Overexpressed in Atopic Dermatitis

  2012cited by this paper
• JAK and STAT signaling molecules in immunoregulation and immune-mediated disease.

  2012influential reference
• Th1 cytokines accentuate but Th2 cytokines attenuate ceramide production in the stratum corneum of human epidermal equivalents: an implication for the disrupted barrier mechanism in atopic dermatitis.

  2012cited by this paper
• Functions of thymic stromal lymphopoietin in immunity and disease

  2012cited by this paper
• Th17 and Th22 in skin allergy.

  2012cited by this paper
• Foxp3+ cells control Th2 responses in a murine model of atopic dermatitis.

  2012cited by this paper
• Inflammation‐Driven Dermal Lymphangiogenesis in Atopic Dermatitis is Associated with CD11b+ Macrophage Recruitment and VEGF‐C Up‐regulation in the IL‐4‐Transgenic Mouse Model

  2012influential reference
• Regulation of immunological balance by sustained interferon-γ gene transfer for acute phase of atopic dermatitis in mice

  2012cited by this paper
• Molecular and clinical rationale for therapeutic targeting of interleukin‐5 and its receptor

  2012cited by this paper
• Abnormal epidermal barrier in the pathogenesis of atopic dermatitis.

  2012cited by this paper
• IL-4 regulates chemokine CCL26 in keratinocytes through the Jak1, 2/Stat6 signal transduction pathway: Implication for atopic dermatitis.

  2012cited by this paper
• Signaling by IL-31 and functional consequences.

  2012cited by this paper
• Mechanistic correlations between two itch biomarkers, cytokine interleukin‐31 and neuropeptide β‐endorphin, via STAT3/calcium axis in atopic dermatitis

  2012cited by this paper
• Pyridone 6, a Pan-JAK Inhibitor, Ameliorates Allergic Skin Inflammation of NC/Nga Mice via Suppression of Th2 and Enhancement of Th17

  2011cited by this paper
• Genomic views of STAT function in CD4+ T helper cell differentiation

  2011cited by this paper
• The role of regulatory T cells in atopic dermatitis.

  2011cited by this paper
• Defective IL-10 signaling in hyper-IgE syndrome results in impaired generation of tolerogenic dendritic cells and induced regulatory T cells

  2011cited by this paper
• Hyperimmunoglobulin E syndromes in pediatrics

  2011cited by this paper
• The transcription factor STAT3 is required for T helper 2 cell development.

  2011cited by this paper
• Regulatory T cells in cutaneous immune responses.

  2011cited by this paper
• The antimicrobial skin barrier in patients with atopic dermatitis.

  2011cited by this paper
• SOCS2 regulates T helper type 2 differentiation and the generation of type 2 allergic responses

  2011cited by this paper
• Functional effects of interleukin 31 in human primary keratinocytes

  2011cited by this paper
• Contrasting pathogenesis of atopic dermatitis and psoriasis--part II: immune cell subsets and therapeutic concepts.

  2011cited by this paper
• Transcriptional regulation by STAT6

  2011cited by this paper
• Decrease in circulating Th17 cells correlates with increased levels of CCL17, IgE and eosinophils in atopic dermatitis.

  2011cited by this paper
• The Th2 systemic immune milieu enhances cutaneous inflammation in the K14-IL-4-transgenic atopic dermatitis model.

  2011cited by this paper
• Contrasting pathogenesis of atopic dermatitis and psoriasis--part I: clinical and pathologic concepts.

  2011cited by this paper
• Th2 Cytokines and Atopic Dermatitis.

  2011cited by this paper
• Interleukin 13 receptors as biochemical markers in atopic patients.

  2011cited by this paper
• Activation of human eosinophils and epidermal keratinocytes by Th2 cytokine IL-31: implication for the immunopathogenesis of atopic dermatitis.

  2010cited by this paper
• Regulation of the T helper cell type 2 (Th2)/T regulatory cell (Treg) balance by IL‐4 and STAT6

  2010cited by this paper
• Signal transduction pathways and transcriptional regulation in Th17 cell differentiation.

  2010cited by this paper
• Analysis of eotaxin 1/CCL11, eotaxin 2/CCL24 and eotaxin 3/CCL26 expression in lesional and non-lesional skin of patients with atopic dermatitis.

  2010cited by this paper
• Signal transduction by the atopy-associated human thymic stromal lymphopoietin (TSLP) receptor depends on Janus kinase function

  2010cited by this paper
• Defects in Jak-STAT-mediated cytokine signals cause hyper-IgE syndrome: lessons from a primary immunodeficiency.

  2009cited by this paper
• Mast cells in atopic dermatitis.

  2009cited by this paper
• VCAM-1 blockade delays disease onset, reduces disease severity and inflammatory cells in an atopic dermatitis model

  2009cited by this paper
• Exaggerated IL-17 response to epicutaneous sensitization mediates airway inflammation in the absence of IL-4 and IL-13.

  2009cited by this paper
• Low‐dose cyclosporine A therapy increases the regulatory T cell population in patients with atopic dermatitis

  2009cited by this paper
• Priming for T helper type 2 differentiation by interleukin 2-mediated induction of IL-4 receptor α chain expression

  2008cited by this paper
• IL-4 Is a Critical Determinant in the Generation of Allergic Inflammation Initiated by a Constitutively Active Stat6

  2008cited by this paper
• The prevalence of atopic triad in children with physician-confirmed atopic dermatitis.

  2008cited by this paper
• Th2 cytokines act on S100/A11 to downregulate keratinocyte differentiation.

  2008cited by this paper
• IL-5 and eosinophilia.

  2008cited by this paper
• The development of atopic dermatitis is independent of Immunoglobulin E up‐regulation in the K14‐IL‐4 SKH1 transgenic mouse model

  2008cited by this paper
• Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6.

  2008cited by this paper
• What causes itch in atopic dermatitis?

  2008cited by this paper
• Reduced memory B cells in patients with hyper IgE syndrome.

  2008cited by this paper
• Low Expression of the IL-23/Th17 Pathway in Atopic Dermatitis Compared to Psoriasis1

  2008cited by this paper
• The Progression of Inflammation Parallels the Dermal Angiogenesis in a Keratin 14 IL‐4‐Transgenic Model of Atopic Dermatitis

  2008cited by this paper
• Cytokine modulation of atopic dermatitis filaggrin skin expression.

  2007cited by this paper
• STAT 3 Regulates Cytokine-mediated Generation of Inflammatory Helper T Cells *

  2007cited by this paper
• STAT3 Regulates Cytokine-mediated Generation of Inflammatory Helper T Cells*

  2007cited by this paper
• Nonredundant roles for Stat5a/b in directly regulating Foxp3.

  2007cited by this paper
• Cytokine milieu of atopic dermatitis skin subverts the innate immune response to vaccinia virus.

  2006cited by this paper
• STAT1 phosphorylation and cleavage is regulated by the histamine (H4) receptor in human atopic and non-atopic lymphocytes.

  2006cited by this paper
• The contribution of keratinocytes to the pathogenesis of atopic dermatitis.

  2006cited by this paper
• CCL27 is a critical factor for the development of atopic dermatitis in the keratin-14 IL-4 transgenic mouse model.

  2006cited by this paper
• Mechanism of HBD-3 deficiency in atopic dermatitis.

  2006cited by this paper
• Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity.

  2006cited by this paper
• The disease progression in the keratin 14 IL‐4‐transgenic mouse model of atopic dermatitis parallels the up‐regulation of B cell activation molecules, proliferation and surface and serum IgE

  2005cited by this paper
• Interleukin-10 downregulates anti-microbial peptide expression in atopic dermatitis.

  2005cited by this paper
• Stat3 Dimerization Regulated by Reversible Acetylation of a Single Lysine Residue

  2005cited by this paper
• Much Atopy about the Skin: Genome-Wide Molecular Analysis of Atopic Eczema

  2005cited by this paper
• Association of a STAT 6 haplotype with elevated serum IgE levels in a population based cohort of white adults

  2004cited by this paper
• Keratinocytes in Atopic dermatitis: Inflammatory signals

  2004cited by this paper
• The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response.

  2004cited by this paper
• Early up‐regulation of Th2 cytokines and late surge of Th1 cytokines in an atopic dermatitis model

  2004cited by this paper
• Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice

  2004cited by this paper
• Effects of histamine on Th1/Th2 cytokine balance.

  2003cited by this paper
• Significant elevation of serum levels of eotaxin‐3/CCL26, but not of eotaxin‐2/CCL24, in patients with atopic dermatitis: serum eotaxin‐3/CCL26 levels reflect the disease activity of atopic dermatitis

  2003cited by this paper
• Molecular cloning and identification of the human interleukin 13 alpha 2 receptor (IL-13Ra2) promoter.

  2003cited by this paper
• JAK-STAT signaling in asthma.

  2002cited by this paper
• Development of Atopic Dermatitis-Like Skin Lesions in STAT6-Deficient NC/Nga Mice1

  2002cited by this paper
• Histamine utilizes JAK-STAT pathway in regulating cytokine production.

  2001cited by this paper
• Regulation of IL-13 production by histamine in cloned murine T helper type 2 cells.

  2001cited by this paper
• Novel dinucleotide repeat polymorphism in the first exon of the STAT‐6 gene is associated with allergic diseases

  2001cited by this paper
• Expression of interleukin-4 in the epidermis of transgenic mice results in a pruritic inflammatory skin disease: an experimental animal model to study atopic dermatitis.

  2001influential reference
• DNA Binding Specificity of Different STAT Proteins

  2001cited by this paper
• IL-4/IL-13 signaling beyond JAK/STAT.

  2000cited by this paper
• Serine phosphorylation of STATs

  2000cited by this paper
• STAT6 deficiency in a mouse model of allergen‐induced airways inflammation abolishes eosinophilia but induces infiltration of CD8+ T cells

  1999cited by this paper
• Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils.

  1999cited by this paper
• Binding of IL-4 to the IL-13Ralpha(1)/IL-4Ralpha receptor complex leads to STAT3 phosphorylation but not to its nuclear translocation.

  1999cited by this paper
• Functional Roles of STAT Family Proteins: Lessons from Knockout Mice

  1999cited by this paper
• Role of JAK2 signal transductional pathway in activation and survival of human peripheral eosinophils by interferon‐gamma (IFN‐γ)

  1999cited by this paper
• Janus kinases and signal transducers and activators of transcription: their roles in cytokine signaling, development and immunoregulation

  1999cited by this paper
• Binding of IL‐4 to the IL‐13Rα1/IL‐4Rα receptor complex leads to STAT3 phosphorylation but not to its nuclear translocation

  1999cited by this paper
• Enhanced expression of eotaxin and CCR3 in atopic dermatitis.

  1999cited by this paper
• The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation

  1997cited by this paper
• IL-5 and IL-5 receptor in asthma.

  1997cited by this paper
• Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted State6 gene

  1996cited by this paper
• Mutation of Jak3 in a Patient with SCID: Essential Role of Jak3 in Lymphoid Development

  1995cited by this paper
• [The role of eosinophilic granulocytes for the pathogenesis of atopic dermatitis /neurodermatitis. Eosinophilic products as markers of disease activity].

  1993cited by this paper
• Disruption of the murine IL-4 gene blocks Th2 cytokine responses

  1993cited by this paper
• Dermal deposition of eosinophil-granule major basic protein in atopic dermatitis. Comparison with onchocerciasis.

  1985cited by this paper

• Eosinophilic proteins and neuropeptides, cytokine profile in children with atopic dermatitis and chronic gastroduodenitis

  2026cites this paper
• Prurigo Nodularis and the Pain Cascade: Understanding the Pathogenesis and Approach to Management.

  2026cites this paper
• Advances and Challenges in the Application of Biologics for Chronic Inflammatory Skin Diseases

  2026cites this paper
• Ruxolitinib cream improves outcomes in atopic dermatitis: An updated systematic review and meta‐analysis

  2026cites this paper
• Therapeutic Effects of Sigesbeckia pubescens Makino Against Atopic Dermatitis-Like Skin Inflammation Through the JAK2/STAT Signaling Pathway

  2025cites this paper
• Atopic Dermatitis Management: from Conventional Therapies to Biomarker-Driven Treatment Approaches

  2025cites this paper
• Overlapping features of atopic dermatitis and alopecia areata: from pathogenesis to treatment

  2025influential citation
• Development and evaluation of two whole-blood flow cytometry protocols for monitoring patients treated with JAK inhibitors

  2025cites this paper
• Therapeutic efficacy and safety of topical ruxolitinib in mild-to-moderate atopic dermatitis: a systematic review

  2025cites this paper
• JAK–STAT inhibitory effect of IN‐115314, a novel small molecule inhibitor, and pharmacokinetic/pharmacodynamic study in canine

  2025cites this paper
• The role of LINC00114 in atopic dermatitis: modulating inflammation and epidermal barrier dysfunction

  2025cites this paper
• Comparative efficacy and safety of dupilumab versus newly approved biologics and JAKi in pediatric atopic dermatitis: A systematic review and network meta-analysis

  2025cites this paper
• Comprehensive analysis of protective effects of Loranthus tanakae Franch. and Sav. on ovalbumin-induced atopic dermatitis in mice and TNF-α/INF-γ-stimulated HaCaT cells

  2025cites this paper
• Fibrotic Disease of the Skin and Lung: Shared Pathways, Environmental Drivers, and Therapeutic Opportunities in a Changing Climate

  2025cites this paper
• Isochlorogenic acid A ameliorates atopic dermatitis by modulating JAK/STAT3, NF-κB, and MAPK pathways in a DNFB/PM2.5-induced mouse model.

  2025cites this paper
• Per- and Polyfluoroalkyl Substance-Induced Skin Barrier Disruption and the Potential Role of Calcitriol in Atopic Dermatitis

  2025cites this paper
• Beyond Antihistamines: How Biologic and Small‐Molecule Therapies Are Transforming Chronic Spontaneous Urticaria Care in Adults

  2025cites this paper
• New Treatments in Atopic Dermatitis Update.

  2025cites this paper
• Innovative microbial strategies in atopic dermatitis

  2025cites this paper
• Exosomes and Exosome-Mimetics for Atopic Dermatitis Therapy

  2025cites this paper
• Chinese Herbal Medicine and Their Active Ingredients Involved in the Treatment of Atopic Dermatitis Related Signaling Pathways

  2025cites this paper
• Blood transcriptome signature as indicator and predictor for efficacy of abrocitinib in treatment of atopic dermatitis.

  2025cites this paper
• Immunological Antagonism Between Psoriasis and Atopic Dermatitis: Pathways, Clinical Implications, and Therapeutic Perspectives

  2025cites this paper
• A real-world study to assess the disease control of moderate to severe atopic dermatitis in patients receiving dupilumab therapy, with atopic dermatitis control tool in Gulf countries

  2025cites this paper
• Topical delgocitinib for the treatment of chronic hand eczema

  2025cites this paper
• The role of the skin microbiome in inherited ichthyoses: A systematic review

  2025cites this paper
• Identifying therapeutic targets for allergic asthma through atopic dermatitis–associated genetic mechanisms

  2025cites this paper
• TARGETED BIOLOGICS IN CHILDHOOD ATOPIC DERMATITIS: A COMPREHENSIVE REVIEW OF IMPACT AND INNOVATION

  2025cites this paper
• JAK inhibitors in the management of extra-intestinal manifestations in inflammatory bowel disease

  2025cites this paper
• Network pharmacology and in-silico approaches to elucidate the antimicrobial mechanism of Aesculus assamica Griff. for the treatment of skin infection

  2025cites this paper
• Predicting Favorable Conditions for the Determination of Initial Use of Janus Kinase Inhibitors in Patients with Moderate to Severe Atopic Dermatitis

  2025cites this paper
• JAK inhibitors as a promising therapy for immune-mediated photodermatoses.

  2025cites this paper
• In silico modeling guides identification of novel JAK1 variants associated with immune dysregulation

  2025cites this paper
• Tryptophan, an important link in regulating the complex network of skin immunology response in atopic dermatitis

  2024cites this paper
• Epigenetic Methylation Changes in Pregnant Women: Bisphenol Exposure and Atopic Dermatitis

  2024cites this paper
• Ruxolitinib cream monotherapy demonstrates rapid improvement in the extent and signs of mild to moderate atopic dermatitis across head and neck and other anatomic regions in adolescents and adults: pooled results from 2 phase 3 studies

  2024cites this paper
• Real-World Use of Ruxolitinib Cream: Safety Analysis at 1 Year

  2024cites this paper
• STAT signaling pathways in immune cells and their associated mechanisms in cancer pathogenesis

  2024cites this paper
• JAK/STAT Inhibition Normalizes Lipid Composition in 3D Human Epidermal Equivalents Challenged with Th2 Cytokines

  2024influential citation
• Topical Therapy for Atopic Dermatitis: What is New and the New Paradigm.

  2024cites this paper
• Medicinal chemistry perspective of JAK inhibitors: synthesis, biological profile, selectivity, and structure activity relationship

  2024cites this paper
• Bioinformatics insights into transcriptomic biomarkers for atopic dermatitis

  2024cites this paper
• Salvia miltiorrhiza bunge extracts: a promising source for anti-atopic dermatitis activity

  2024cites this paper
• Developmental trajectories of atopic dermatitis with multi-omics approaches in the infant gut: COCOA birth cohort.

  2024cites this paper
• Cytokines reprogram airway sensory neurons in asthma.

  2024cites this paper
• Adverse event of ruxolitinib cream: a real-world analysis based on FDA adverse event reporting system from 2021 to 2024.

  2024cites this paper
• Role of topical tofacitinib in autoimmune skin disorders: An expert opinion

  2024cites this paper
• Preclinical Development of SHR-1819, a Potent Humanized IL-4Rα Antibody for Treating Type 2 Inflammatory Diseases

  2024cites this paper
• Monoclonal Antibodies: Current Advancements and Future Potential for Atopic Dermatitis Therapy.

  2024cites this paper
• Revisiting immunotherapeutic strategies for the management of atopic dermatitis

  2024cites this paper
• Treatment of Atopic Dermatitis in Children

  2024cites this paper
• Cheungsam Seed Husk Extract Reduces Skin Inflammation through Regulation of Inflammatory Mediator in TNF-α/IFN-γ-Induced HaCaT Cells

  2024cites this paper
• Anti‐chitinase‐3‐like 1 antibody attenuated atopic dermatitis‐like skin inflammation through inhibition of STAT3‐dependent CXCL8 expression

  2024cites this paper
• Topical delivery of baricitinib-impregnated nanoemulgel: a promising platform for inhibition of JAK -STAT pathway for the effective management of atopic dermatitis

  2024cites this paper
• Cytokines reprogram airway sensory neurons in asthma

  2024cites this paper
• Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies

  2024influential citation
• PJ‑001, a small‑molecule proteolysis‑targeting chimera, ameliorates atopic dermatitis‑like inflammation in mice by inhibiting the JAK2/STAT3 pathway and repairing the skin barrier.

  2024cites this paper
• Prurigo Nodularis: New insights into pathogenesis and novel therapeutics.

  2024cites this paper
• Application of JAK inhibitors in paradoxical reaction through immune-related dermatoses

  2024cites this paper
• What is novel in the clinical management of pemphigus vulgaris?

  2024cites this paper
• Controversial Issues of Immunopathogenesis of Psoriasis and Atopic Dermatitis

  2024cites this paper
• Regulatory effects of Ishige okamurae extract and Diphlorethohydroxycarmalol on skin barrier function

  2024cites this paper
• Recent progress in tyrosine kinase 2 inhibitors for atopic dermatitis

  2024cites this paper
• Safety, efficacy, and pharmacokinetics of delgocitinib ointment in infants with atopic dermatitis: A phase 3, open-label, and long-term study.

  2023cites this paper
• Epigenetic control of inflammation in Atopic Dermatitis.

  2023cites this paper
• Dysregulated Hippo Signaling Pathway and YAP Activation in Atopic Dermatitis: Insights from Clinical and Animal Studies

  2023cites this paper
• Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions

  2023cites this paper
• In silico Studies of Potential Drug-like Compounds from various Medicinal Plants: The Discovery of JAK1 Inhibitors and JAK3 Inhibitors

  2023cites this paper
• Topical Janus kinase inhibitors in atopic dermatitis: a safety network meta-analysis

  2023cites this paper
• Diagnostic and prognostic importance of biomarkers in the atopic dermatitis endotypes and phenotypes and in the effectiveness assessing of therapy

  2023cites this paper
• Lupeol alleviates atopic dermatitis-like skin inflammation in 2,4-dinitrochlorobenzene/Dermatophagoides farinae extract-induced mice

  2023cites this paper
• Interactions between Malassezia and New Therapeutic Agents in Atopic Dermatitis Affecting Skin Barrier and Inflammation in Recombinant Human Epidermis Model

  2023cites this paper
• Chronic pruritus: from pathophysiology to drug design.

  2023cites this paper
• The recurrent course of atopic dermatitis: therapeutic options for management of disease and prolongation of remissions

  2023cites this paper
• Perspective insights of small molecules, phytoconstituents and biologics in the management of psoriasis: A focus on targeting major inflammatory cytokine pathways.

  2023cites this paper
• Green HPTLC - Densitometric approach for quantitation of Ruxolitinib in bulk and marketed formulation

  2023cites this paper
• EXTRACELLULAR MATRIX REMODELING IN ATOPIC DERMATITIS HARNESSES THE ONSET OF AN ASTHMATIC PHENOTYPE AND IS A POTENTIAL CONTRIBUTOR TO THE ATOPIC MARCH.

  2023cites this paper
• Baricitinib blocks cytokine mediated downregulation of PAD1 in human keratinocytes: a possible molecular link to the effects of JAK-inhibitors in atopic dermatitis.

  2023cites this paper
• Safety and efficacy of eblasakimab, an IL-13Rα1 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: a phase 1b, multiple-ascending dose study.

  2023cites this paper
• Unveiling Abrocitinib: A Thorough Examination of the 2022 USFDA-Approved Treatment for Atopic Dermatitis (AD)

  2023cites this paper
• Oral JAK Inhibitors for Atopic Dermatitis.

  2023cites this paper
• Dupilumab Efficacy and Safety in Severe Atopic Dermatitis in Children under 6 Years of Age: Two Clinical Cases

  2023cites this paper
• Evaluation of SOCS5 mRNA and its association with serum IL-12 levels and rs41379147 SNP in various subsets of allergic disorders: A case control study.

  2023cites this paper
• The JAK/STAT signalling pathway: Tiny molecules transforming therapeutics

  2023cites this paper
• Lactobacillus for the treatment and prevention of atopic dermatitis: Clinical and experimental evidence

  2023cites this paper
• Development and application of novel peptide-formulated nanoparticles for treatment of atopic dermatitis.

  2023cites this paper
• Effect of Physalis angulata leaf extract cream on Interleukin-4, Interleukin-6, and Immunoglobulin-E in mice with induced atopic dermatitis

  2023cites this paper
• Securinega suffruticosa extract alleviates atopy-like lesions in NC/Nga mice via inhibition of the JAK1-STAT1/3 pathway.

  2023cites this paper
• Ocular instillation of conditioned medium from mesenchymal stem cells is effective for dry eye syndrome by improving corneal barrier function

  2023cites this paper
• Ultra-High Frequency UltraSound (UHFUS) Assessment of Barrier Function in Moderate-to-Severe Atopic Dermatitis during Dupilumab Treatment

  2023cites this paper
• Modulation of Neuroimmune and Epithelial Dysregulation in Patients With Moderate to Severe Prurigo Nodularis Treated With Nemolizumab

  2023cites this paper
• Alopecia Universalis in an Adolescent Successfully Treated with Upadacitinib—A Case Report and Review of the Literature on the Use of JAK Inhibitors in Pediatric Alopecia Areata

  2023cites this paper
• Therapeutic effects and mechanisms of Ku-Gan formula on atopic dermatitis: A pilot clinical study and modular pharmacology analysis with animal validation.

  2023cites this paper
• Topical and systemic JAK inhibitors in hand eczema – a narrative review

  2023cites this paper
• Upadacitinib for moderate to severe atopic dermatitis.

  2023cites this paper
• The Impact of Air Pollution on Atopic Dermatitis

  2023cites this paper
• Intrinsic Effects of Exposome in Atopic Dermatitis: Genomics, Epigenomics and Regulatory Layers

  2023cites this paper
• Computational and In Vitro Assessment of a Natural Triterpenoid Compound Gedunin against Breast Cancer via Caspase 3 and Janus Kinase/STAT Modulation

  2023cites this paper
• Pathogenesis of allergic diseases and implications for therapeutic interventions

  2023cites this paper
• JAK Inhibitor Use for the Inpatient Dermatologist

  2023cites this paper